Mammalian target of rapamycin (mTOR) is a serine/threonine kinase and regulates cellular metabolism, growth and proliferation. Sirolimus is an mTOR inhibitor and is widely used as an immunosuppressive agent to prevent rejection and/or GVHD in both solid organ and BM transplantation. Sirolimus has advantages over calcineurin inhibitors in induction of immune tolerance. 5, 6 We present two cases of angioedema in the setting of chronic ACEi administration, which may have been precipitated by the concurrent use of sirolimus in the post-hematopoietic SCT (HSCT) setting.
Patient 1 is a 41-year-old African man with homozygous SS disease, complicated by frequent vaso-occlusive pain crises, a tricuspid regurgitant velocity of 2.6 m/s, proteinuria (1577.3 mg/ 24 h) and transfusion-related iron overload (liver iron concentration 23.8 mg/g), who underwent nonmyeloablative allogeneic HSCT from an HLA-matched sister. The conditioning regimen included alemtuzumab (1 mg/kg divided over 5 days) and TBI of 300 cGy. Sirolimus was initiated on day − 1 for GVHD prophylaxis. On post-transplant day 12, he developed upper and lower lip swelling ( Figure 1 ). There was no tongue swelling, stridor or respiratory distress, and no airway obstruction on nasolaryngoscopy. He was transferred to the intensive care unit for monitoring. Lisinopril, which he had been given to treat proteinuria for the previous year, was immediately discontinued. Other medications in addition to sirolimus included ursodiol, cholecalciferol, folate, acyclovir, nystatin and vancomycin. Laboratory findings were significant for a high sirolimus level of 20.5 ng/mL (target range 10-15 ng/mL), a normal C3 and C4 level, and a C1 esterase inhibitor level of 40 mg/dL (reference range 19-37 mg/dL). The patient was treated with i.v. methylprednisolone, diphenhydramine and ranitidine. Sirolimus dosage was reduced toward a target level. Angioedema completely resolved within 24 h. Given the continued need for controlling proteinuria, the angiotensin receptor blocker losartan was substituted for lisinopril. The patient has been maintained on losartan and sirolimus for over a year without recurrence of angioedema.
Patient 2 is a 47-year-old African-American woman with homozygous SS disease, frequent vasoocclusive pain crises, systemic hypertension, proteinuria (227 mg/24 h) and transfusion-related iron overload (LIC 16 mg/g), who underwent a nonmyeloablative allogeneic HSCT from a matched sibling donor. The conditioning regimen was identical to patient 1. Sirolimus was initiated on day − 1 for GVHD prophylaxis. On day 10 post transplantation, she developed a pruritic skin rash on the upper and lower extremities, back and neck, followed by eyelid, lip and facial swelling. There was no tongue swelling or airway obstruction. Her medications were lisinopril, which she had been on for proteinuria for the prior 6 months, amlodipine, sirolimus, penicillin, acyclovir, nystatin, ursodiol, cholecalciferol, fenofibrate, folic acid and a clonidine patch. C3 and C4 levels were normal. Her sirolimus level at the time of the event was slightly high at 16.9 ng/mL. Lisinopril was discontinued and she was treated with diphenhydramine and ranitidine. Sirolimus dose was adjusted per protocol. Her symptoms and signs of angioedema resolved in a week off lisinopril but on sirolimus. She did not have a recurrence of angioedema over the next 15 months.
These two patients developed non-life-threatening angioedema in the early post-HSCT period while being treated with both lisinopril and sirolimus. Although lisinopril is well known to be associated with angioedema, the fact that both patients had been maintained on lisinopril without angioedema for an extended time pre-transplantation, and developed angioedema soon after sirolimus was initiated, at the time of high sirolimus levels, raises the possibility that the two drugs together may synergize in contributing to angioedema.
Several case reports and case series implicate the increased incidence of angioedema when mTOR inhibitors are added to ACEi in the solid organ transplant setting. 7, 8 A retrospective singlecenter study reported a higher incidence of angioedema when both agents were used (6.6%) compared to an ACEi alone (2.2%) or mTOR inhibitor alone (1.2%) in patients undergoing kidney transplantation (odds ratio 3.7; 95% confidence interval 1.5-8.9, P = 0.004). 8 The course of angioedema was easily manageable with rapid resolution of symptoms with a bolus of corticosteroids and/ or discontinuation of ACEi, and none of them needed an intensive care unit monitoring. Eight out of nine patients who had angioedema while on ACEi and mTOR inhibitor and had a continued indication for angiotensin blockade were transitioned to an angiotensin receptor blocker (ARB), and all avoided a recurrence of angioedema despite continued treatment with the mTOR inhibitor. The mechanism for increased incidence of angioedema with the concurrent use of ACEi and mTOR inhibitor is unknown. While the role of concurrent use of both agents in angioedema is tentative, a dose-dependent synergistic interaction was suggested by Stallone et al., 7 who observed angioedema only when full doses of both medications were used, and patients tolerated lower doses of these medications without recurrence of angioedema.
As in most prior reported cases of angioedema occurring in the setting of concurrent use of an mTOR inhibitor and an ACEi, 8 our two patients experienced non-life-threatening angioedema within 2 weeks of concurrent drug administration, while on both lisinopril and sirolimus. Sirolimus levels were high in both patients. ACEi were immediately discontinued and the two patients were empirically treated with methylprednisolone or diphenhydramine and ranitidine. Angioedema had completely resolved within 24 h in patient 1 and majority of the symptoms had resolved in 72 h in patient 2. Neither had recurrence of angioedema, and both were able to continue treatment with sirolimus, an essential immunosuppressant in our HSCT protocol. Among 34 patients who underwent HSCT on the same protocol, 9 patients received concurrent lisinopril and sirolimus and 2 of them (patients 1 and 2) developed angioedema. There were two other patients who were treated with losartan and sirolimus concurrently, and neither developed angioedema.
The incidence of ACEi-induced angioedema is reported to be higher in African Americans 9 and it may be due to genetic polymorphism in the neprilysin gene. 10 Genetic predisposition may play a role in our patients in developing angioedema.
To our best knowledge, this is the first report of angioedema with the concurrent mTOR inhibitor and ACEi use in the HSCT setting. Caution should be used when starting an mTOR inhibitor in patients already taking an ACEi, or vice versa, in this patient population. Substitution of ACEi for ARB should be considered given low rate of cross reactivity.
